IN BRIEF: Oxford Biomedica inks new licensing and option deal
Oxford BioMedica PLC - Oxford, England-based gene and cell therapy developer - Enters a five-year licensing and option agreement with Viral Vector Manufacturing Facility, an Australian contract development and manufacturing organisation (CDMO) and "the country's first commercial manufacturing facility of its kind", having signed a non-binding terms sheet in October. VVMF will have a non-exclusive global licence to use Oxford BioMedica's inAAVate platform "know-how and intellectual property", and an option to extend the licence to the LentiVector platform. OXB says it will receive a low single-digit million licence fee and is eligible for future platform use payments. Expects the contract to enable VVMF "to accelerate its operational and commercial readiness to provide advanced viral vector technologies to customers, capturing global demand with a particular focus on the fast-growing APAC region, and positioning Australia as a regional hub for high‑quality cell and gene therapy manufacturing." Read More